抗cd20单克隆抗体在慢性淋巴细胞白血病中的最新进展。

IF 3.6 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2018-09-01 Epub Date: 2018-08-10 DOI:10.1080/14712598.2018.1508444

Mitchell Evers, Margot Jak, J H W Leusen

{"title":"抗cd20单克隆抗体在慢性淋巴细胞白血病中的最新进展。","authors":"Mitchell Evers, Margot Jak, J H W Leusen","doi":"10.1080/14712598.2018.1508444","DOIUrl":null,"url":null,"abstract":"Introduction: In more recent years, anti-CD20 monoclonal antibodies have become the backbone in the treatment of chronic lymphocytic leukemia (CLL). Historically, these antibodies were typically combined with chemotherapeutic agents. At present, therapeutic outcomes are significantly improving with the introduction of several novel targeted drugs to the clinical repertoire.Areas covered: In this review, we summarize the current clinical standard together with the latest developments in the field of anti-CD20 antibodies against CLL. In addition, novel promising drugs against CLL are discussed, as well as their potential for combination with anti-CD20 monoclonal antibodies.Expert opinion: At present, there are three different anti-CD20 monoclonal antibodies approved for the treatment of CLL with diverse effector mechanisms. These antibodies provide a robust foundation for combination therapy with novel molecules. Current research should be focused on reducing toxicity and reaching long-lasting remissions. There is still much to gain regarding the optimization of treatment combinations and dosing schedules for CLL. Overcoming the limitations of currently used anti-CD20 antibodies will be critical to further improve the efficacy of CLL therapy.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":"18 9","pages":"973-982"},"PeriodicalIF":3.6000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/14712598.2018.1508444","citationCount":"7","resultStr":"{\"title\":\"The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.\",\"authors\":\"Mitchell Evers, Margot Jak, J H W Leusen\",\"doi\":\"10.1080/14712598.2018.1508444\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: In more recent years, anti-CD20 monoclonal antibodies have become the backbone in the treatment of chronic lymphocytic leukemia (CLL). Historically, these antibodies were typically combined with chemotherapeutic agents. At present, therapeutic outcomes are significantly improving with the introduction of several novel targeted drugs to the clinical repertoire.Areas covered: In this review, we summarize the current clinical standard together with the latest developments in the field of anti-CD20 antibodies against CLL. In addition, novel promising drugs against CLL are discussed, as well as their potential for combination with anti-CD20 monoclonal antibodies.Expert opinion: At present, there are three different anti-CD20 monoclonal antibodies approved for the treatment of CLL with diverse effector mechanisms. These antibodies provide a robust foundation for combination therapy with novel molecules. Current research should be focused on reducing toxicity and reaching long-lasting remissions. There is still much to gain regarding the optimization of treatment combinations and dosing schedules for CLL. Overcoming the limitations of currently used anti-CD20 antibodies will be critical to further improve the efficacy of CLL therapy.\",\"PeriodicalId\":12084,\"journal\":{\"name\":\"Expert Opinion on Biological Therapy\",\"volume\":\"18 9\",\"pages\":\"973-982\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2018-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/14712598.2018.1508444\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Biological Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14712598.2018.1508444\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/8/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2018.1508444","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/8/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 7

摘要

近年来，抗cd20单克隆抗体已成为慢性淋巴细胞白血病(CLL)治疗的骨干。历史上，这些抗体通常与化疗药物联合使用。目前，随着几种新型靶向药物的引入，治疗效果正在显著改善。涉及领域:在本文中，我们总结了目前的临床标准以及抗cd20抗体治疗CLL的最新进展。此外，本文还讨论了抗CLL的新药物，以及它们与抗cd20单克隆抗体联合的潜力。专家意见:目前，有三种不同的抗cd20单克隆抗体被批准用于治疗CLL，具有不同的效应机制。这些抗体为新分子联合治疗提供了坚实的基础。目前的研究应侧重于降低毒性和达到长期缓解。关于CLL的治疗组合和给药方案的优化，仍有很多需要改进的地方。克服目前使用的抗cd20抗体的局限性对于进一步提高CLL治疗的疗效至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.

Introduction: In more recent years, anti-CD20 monoclonal antibodies have become the backbone in the treatment of chronic lymphocytic leukemia (CLL). Historically, these antibodies were typically combined with chemotherapeutic agents. At present, therapeutic outcomes are significantly improving with the introduction of several novel targeted drugs to the clinical repertoire.

Areas covered: In this review, we summarize the current clinical standard together with the latest developments in the field of anti-CD20 antibodies against CLL. In addition, novel promising drugs against CLL are discussed, as well as their potential for combination with anti-CD20 monoclonal antibodies.

Expert opinion: At present, there are three different anti-CD20 monoclonal antibodies approved for the treatment of CLL with diverse effector mechanisms. These antibodies provide a robust foundation for combination therapy with novel molecules. Current research should be focused on reducing toxicity and reaching long-lasting remissions. There is still much to gain regarding the optimization of treatment combinations and dosing schedules for CLL. Overcoming the limitations of currently used anti-CD20 antibodies will be critical to further improve the efficacy of CLL therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.